NASDAQ$MIST
Milestone Pharmaceuticals Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
MIST reported Q3 2025 revenue of $8.5M, a net loss of $28.0M.
For Q3 2025, MIST reported Revenue was $8.5M, net loss was $28.0M. The filing discusses operating performance, liquidity, and outlook in MD&A.
- Revenue $8.5M for Q3 2025.
- Net loss $28.0M.
- MD&A covers R&D, cash runway, and sector-specific risks.
Headline financials
Revenue & EPS history
Milestone Pharmaceuticals · Revenue · Quarterly
$8.5M
Forward guidance
Outlook focuses on cash runway, pipeline milestones, and cost discipline as the company works toward profitability.
Tailwinds
- Cash and equivalents support operations into upcoming milestones.
- Clinical or product pipeline progress noted in MD&A.
Headwinds
- Ongoing operating losses and R&D spend pressure near-term earnings.
- Financing, dilution, or partnership timing may affect liquidity.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2025
+2.5%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+1.5%
Avg return
30 days after
67%
18 / 27 earnings
Positive
+24.1%
Q3 2021
Best reaction
-23.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | — | — | — | |
| Q1 2026 | -9.5% | -23.2% | — | |
| Q3 2025 | +1.0% | +21.5% | +26.2% | |
| Q2 2025 | +7.1% | +9.7% | +23.2% | |
| Q1 2025 | -1.7% | +8.4% | +38.7% | |
| Q4 2024 | +7.9% | -53.7% | -38.9% | |
| Q3 2024 | -5.2% | -12.4% | -4.1% | |
| Q1 2024 | +1.2% | +2.4% | -16.5% | |
| Q4 2023 | +16.0% | +20.7% | +9.3% | |
| Q3 2023 | -23.0% | -24.4% | -13.7% | |
| Q2 2023 | +1.6% | +2.6% | -7.1% | |
| Q1 2023 | +12.8% | +0.5% | +1.3% | |
| Q4 2022 | -4.0% | -0.3% | -9.0% | |
| Q3 2022 | +13.0% | +7.1% | -0.7% | |
| Q2 2022 | +3.6% | +5.3% | +29.2% | |
| Q1 2022 | -2.5% | +1.6% | +1.6% | |
| Q4 2021 | +12.4% | +17.5% | +22.0% | |
| Q3 2021 | +24.1% | +13.9% | +4.5% | |
| Q2 2021 | +0.2% | +2.1% | +7.1% | |
| Q1 2021 | +0.5% | +2.9% | +8.1% | |
| Q4 2020 | -6.6% | -2.4% | -4.2% | |
| Q3 2020 | +6.1% | +6.0% | +19.8% | |
| Q2 2020 | -1.8% | +0.3% | -12.2% | |
| Q1 2020 | +0.3% | +4.8% | +29.5% | |
| Q4 2019 | +7.4% | +8.7% | -90.4% | |
| Q3 2019 | -4.2% | -1.2% | -7.2% | |
| Q2 2019 | +7.8% | +9.9% | +38.1% | |
| Q1 2019 | +3.4% | -4.5% | -16.2% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro